Hero

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

1

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

2

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Discover all news

Carousel

Social Feed

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

5 days ago

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…

1 week ago

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…

RT @mnmconferences: Next-Gen Regenerative Medicine & Tissue Engineering Conference Day 2 Update - Peggy Sotiropoulou R&D Manager @CelyadSA…

1 week ago

RT @mnmconferences: Next-Gen Regenerative Medicine & Tissue Engineering Conference Day 2 Update - Peggy Sotiropoulou R&D Manager @CelyadSA…

Interview de Christian Homsy, CEO de Celyad, dans @lecho suite à l'annonce de ce matin concernant notre accord avec… https://t.co/6qjCp2camY

1 week ago

Interview de Christian Homsy, CEO de Celyad, dans @lecho suite à l'annonce de ce matin concernant notre accord avec… https://t.co/6qjCp2camY

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

5 days ago

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…

1 week ago

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…

RT @mnmconferences: Next-Gen Regenerative Medicine & Tissue Engineering Conference Day 2 Update - Peggy Sotiropoulou R&D Manager @CelyadSA…

1 week ago

RT @mnmconferences: Next-Gen Regenerative Medicine & Tissue Engineering Conference Day 2 Update - Peggy Sotiropoulou R&D Manager @CelyadSA…

Interview de Christian Homsy, CEO de Celyad, dans @lecho suite à l'annonce de ce matin concernant notre accord avec… https://t.co/6qjCp2camY

1 week ago

Interview de Christian Homsy, CEO de Celyad, dans @lecho suite à l'annonce de ce matin concernant notre accord avec… https://t.co/6qjCp2camY